Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Cassava Sciences Inc
A US pharmaceutical company focused on treatments for brain and nervous-system diseases, most notably simufilam, an experimental oral drug for Alzheimer's disease. It began in 1998 as Pain Therapeutics, founded in Austin, Texas, by Remi Barbier and Jacques Barbut, before rebranding as Cassava Sciences in 2019 to pivot toward neuroscience — a name drawn from the cassava plant, whose starchy roots are a food staple in South America. The company later renamed itself Filana Therapeutics.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement